Mid-Term Outcomes Following Percutaneous Pulmonary Valve Implantation Using the "Folded Melody Valve" Technique.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
04 2021
Historique:
pubmed: 18 3 2021
medline: 16 10 2021
entrez: 17 3 2021
Statut: ppublish

Résumé

The folded valve is a manual shortening of the Melody device, which has been validated as a valuable therapeutic option for the management of dysfunctional right ventricular outflow tracts needing a short valved stent. In this article, we aimed to evaluate, in a multicenter cohort, the mid-term outcomes of patients in whom a percutaneous pulmonary valve implantation was performed using the folded valve technique. A 2012 to 2018 retrospective multicenter study was performed in 7 European institutions. All patients who benefit from percutaneous pulmonary valve implantation with a folded Melody valve were included. A total of 49 patients (median age, 19 years [range 4–56], 63% male) were included. The primary percutaneous pulmonary valve implantation indication was right ventricular outflow tract stenosis (n=19; 39%), patched native right ventricular outflow tracts were the most common substrate (n=15; 31%). The folded technique was mostly used in short right ventricular outflow tracts (n=28; 57%). Procedural success was 100%. After a median follow-up of 28 months (range, 4–80), folded Melody valve function was comparable to the immediate postimplantation period (mean transvalvular peak velocity=2.6±0.6 versus 2.4±0.6 m/s, P>0.1; only 2 patients had mild pulmonary regurgitation). Incidence rate of valve-related reinterventions was 2.1% per person per year (95% CI, 0.1%–3.9%). The probability of survival without valve-related reinterventions at 36 months was 90% (95% CI, 76%–100%). The folded Melody valve is a safe technique with favorable mid-term outcomes up to 6.5 years after implantation, comparable with the usual Melody valve implantation procedure. Complications and reinterventions rates were low, making this technique relevant in selected patients.

Sections du résumé

BACKGROUND
The folded valve is a manual shortening of the Melody device, which has been validated as a valuable therapeutic option for the management of dysfunctional right ventricular outflow tracts needing a short valved stent. In this article, we aimed to evaluate, in a multicenter cohort, the mid-term outcomes of patients in whom a percutaneous pulmonary valve implantation was performed using the folded valve technique.
METHODS
A 2012 to 2018 retrospective multicenter study was performed in 7 European institutions. All patients who benefit from percutaneous pulmonary valve implantation with a folded Melody valve were included.
RESULTS
A total of 49 patients (median age, 19 years [range 4–56], 63% male) were included. The primary percutaneous pulmonary valve implantation indication was right ventricular outflow tract stenosis (n=19; 39%), patched native right ventricular outflow tracts were the most common substrate (n=15; 31%). The folded technique was mostly used in short right ventricular outflow tracts (n=28; 57%). Procedural success was 100%. After a median follow-up of 28 months (range, 4–80), folded Melody valve function was comparable to the immediate postimplantation period (mean transvalvular peak velocity=2.6±0.6 versus 2.4±0.6 m/s, P>0.1; only 2 patients had mild pulmonary regurgitation). Incidence rate of valve-related reinterventions was 2.1% per person per year (95% CI, 0.1%–3.9%). The probability of survival without valve-related reinterventions at 36 months was 90% (95% CI, 76%–100%).
CONCLUSIONS
The folded Melody valve is a safe technique with favorable mid-term outcomes up to 6.5 years after implantation, comparable with the usual Melody valve implantation procedure. Complications and reinterventions rates were low, making this technique relevant in selected patients.

Identifiants

pubmed: 33726503
doi: 10.1161/CIRCINTERVENTIONS.120.009707
pmc: PMC8055198
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e009707

Références

Arch Cardiovasc Dis. 2014 Nov;107(11):635-42
pubmed: 25241221
EuroIntervention. 2014 Feb;9(10):1237-40
pubmed: 24561739
Can J Cardiol. 2018 Jun;34(6):812.e5-812.e7
pubmed: 29801748
Eur Heart J. 2019 Jul 14;40(27):2255-2264
pubmed: 31005985
Circulation. 2015 Jun 2;131(22):1960-70
pubmed: 25944758
Circ Cardiovasc Interv. 2017 Feb;10(2):
pubmed: 28153843
Circ Cardiovasc Interv. 2011 Dec 1;4(6):602-14
pubmed: 22075927
JACC Cardiovasc Interv. 2017 Sep 11;10(17):1746-1759
pubmed: 28823778
Arch Cardiovasc Dis. 2018 Aug - Sep;111(8-9):497-506
pubmed: 29530718
Heart Rhythm. 2016 Nov;13(11):2135-2141
pubmed: 27453127
Circ Cardiovasc Interv. 2014 Jun;7(3):374-80
pubmed: 24867892
Lancet. 2000 Oct 21;356(9239):1403-5
pubmed: 11052583
Circ Cardiovasc Interv. 2014 Apr;7(2):142-8
pubmed: 24569596
EuroIntervention. 2017 Sep 24;13(AA):AA60-AA67
pubmed: 28942387
Circ Cardiovasc Interv. 2012 Dec;5(6):862-70
pubmed: 23212395
JACC Cardiovasc Interv. 2018 Oct 8;11(19):1909-1916
pubmed: 30219326
JACC Cardiovasc Interv. 2020 Feb 10;13(3):e21-e22
pubmed: 31734303
JACC Cardiovasc Interv. 2017 Jul 24;10(14):1449-1458
pubmed: 28728659
Circ Cardiovasc Interv. 2015 Feb;8(2):e002260
pubmed: 25652320
Circulation. 2010 Aug 3;122(5):507-16
pubmed: 20644013
Circ Cardiovasc Interv. 2018 Nov;11(11):e007145
pubmed: 30571200
Int J Cardiol. 2015 Nov 1;198:201-5
pubmed: 26173058
JACC Cardiovasc Interv. 2018 Oct 8;11(19):1920-1929
pubmed: 30286853
Catheter Cardiovasc Interv. 2015 Mar;85(4):604-10
pubmed: 25413082
Circulation. 2007 Mar 20;115(11):1392-7
pubmed: 17339542

Auteurs

Zakaria Jalal (Z)

Bordeaux University Hospital (CHU), Department of Pediatric and Adult Congenital Cardiology, Pessac, France (Z.J., E.V., J.-B.T.).
IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Pessac-Bordeaux, France (Z.J., E.V., X.P., J.-B.T.).
INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, France (Z.J., E.V., X.P., J.-B.T.).

Estíbaliz Valdeolmillos (E)

Bordeaux University Hospital (CHU), Department of Pediatric and Adult Congenital Cardiology, Pessac, France (Z.J., E.V., J.-B.T.).
IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Pessac-Bordeaux, France (Z.J., E.V., X.P., J.-B.T.).
INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, France (Z.J., E.V., X.P., J.-B.T.).

Sophie Malekzadeh-Milani (S)

Department of Congenital and Pediatric Cardiology, Centre de Reference Malformations Cardiaques Congenitales Complexes-M3C, Necker Hospital for Sick Children, Assistance Publique des Hôpitaux de Paris, Pediatric Cardiology, France (S.M.-M.).

Andreas Eicken (A)

Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center Munich at the TU Munich, Germany (A.E., S.G.).

Stanimir Georgiev (S)

Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center Munich at the TU Munich, Germany (A.E., S.G.).

Michael Hofbeck (M)

Department of Pediatric Cardiology, University Children's Hospital, Tuebingen, Germany (M.H., L.S.).

Ludger Sieverding (L)

Department of Pediatric Cardiology, University Children's Hospital, Tuebingen, Germany (M.H., L.S.).

Marc Gewillig (M)

Department of Pediatric Cardiology, University Hospitals Leuven, Belgium (M.G.).

Caroline Ovaert (C)

Department of Pediatric Cardiology and Congenital Heart Disease, AP-HM, Timone enfants, Hopital de la Timone, Provence-Alpes-Côte d'Azur, France (C.O.).

Helene Bouvaist (H)

Cardiology Department, CHU Grenoble, France (H.B.).

Xavier Pillois (X)

IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Pessac-Bordeaux, France (Z.J., E.V., X.P., J.-B.T.).
INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, France (Z.J., E.V., X.P., J.-B.T.).

Jean-Benoit Thambo (JB)

Bordeaux University Hospital (CHU), Department of Pediatric and Adult Congenital Cardiology, Pessac, France (Z.J., E.V., J.-B.T.).
IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Pessac-Bordeaux, France (Z.J., E.V., X.P., J.-B.T.).
INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, France (Z.J., E.V., X.P., J.-B.T.).

Younes Boudjemline (Y)

Cardiac Catheterization Laboratories, Sidra Heart Center, Sidra Medicine, Doha, Qatar (Y.B.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH